Market Cap 255.23M
Revenue (ttm) 92.13M
Net Income (ttm) -18.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 119.58
Profit Margin -20.25%
Debt to Equity Ratio 0.28
Volume 128,638
Avg Vol 272,756
Day's Range N/A - N/A
Shares Out 18.50M
Stochastic %K 8%
Beta 1.34
Analysts Strong Sell
Price Target $15.33

Company Profile

OptimizeRx Corporation operates as a digital healthcare technology company. The company offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, HUB awa...

Industry: Health Information Services
Sector: Healthcare
Phone: 248-651-6568
Address:
260 Charles Street, Suite 302, Waltham, United States
Eastern_Edge
Eastern_Edge Jul. 29 at 5:10 PM
$OPRX Bears completely silent after year end and Q1 earnings. Sad bears absolutely obliterated into the shadow realm LMAO
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 28 at 11:08 PM
$OPRX Excellent article that nails exactly where OPRX stands right now. So if you want to update your OPRX knowledge or get acquainted with OPRX, this is a must read. https://beyondspx.com/article/optimizerx-leveraging-integrated-tech-and-data-for-profitable-growth-nasdaq-oprx
0 · Reply
ZacksResearch
ZacksResearch Jul. 25 at 4:40 PM
$OPRX — Is this digital health player the real deal? 🚀 OptimizeRx delivered 11% year-over-year revenue growth and a shift to a subscription model in Q1 2025, with over 5% of projected annual revenues already converted to subscriptions. Despite risks like macro constraints and regulatory shifts, a Zacks Rank #1 suggests strong buy potential. See what makes the investment case strong for OptimizeRx 👉 https://www.zacks.com/stock/news/2616875/oprx-delivers-solid-q1-earnings-but-can-it-sustain-the-momentum?cid=sm-stocktwits-2-2616875-body-3835&ADID=SYND_STOCKTWITS_TWEET_2_2616875_BODY_3835
0 · Reply
ZacksResearch
ZacksResearch Jul. 25 at 12:29 PM
$OPRX delivers solid Q1 — but can it keep up the pace? 11% revenue growth and improved EBITDA show strength, but long-term upside depends on scaling subscriptions and margin mix improvements. Full momentum breakdown here 👉 https://www.zacks.com/stock/news/2616875/oprx-delivers-solid-q1-earnings-but-can-it-sustain-the-momentum?cid=sm-stocktwits-2-2616875-teaser-3818&ADID=SYND_STOCKTWITS_TWEET_2_2616875_TEASER_3818
0 · Reply
WOLFSTREET
WOLFSTREET Jul. 25 at 9:04 AM
$OPRX is on a CC LIST, play this horse until it runs out, and it has a ways to go, then move your winnings to $GDRX , the sleeping pills should have worn off by then, but otherwise you can just check back with CC for a 60 second update. I promise its quick, I just did both in less than 2 minutes.
0 · Reply
WOLFSTREET
WOLFSTREET Jul. 25 at 9:00 AM
Only reason $OPRX is beating $GDRX on the track is because OPRX has been chosen by the market to run, while market has GDRX on sleeping pills. Things will flip when pills wear off.
0 · Reply
tijsd
tijsd Jul. 23 at 2:27 PM
$PAYS if your bullish on pays, check $OPRX
0 · Reply
ZacksResearch
ZacksResearch Jul. 18 at 1:28 PM
$OPRX up 187.9% YTD — still room to run? 🚀 💡 11% year-over-year revenue growth and a 25% script lift highlight its strategic value. 🔍 With over 80% of 2025 revenues already contracted, the shift to subscription-based models offers margin stability. Discover why OPRX's transformation might be just getting started 👉 https://www.zacks.com/stock/news/2591316/can-oprxs-patient-engagement-tools-win-amid-fierce-competition?cid=sm-stocktwits-2-2591316-body-2533&ADID=SYND_STOCKTWITS_TWEET_2_2591316_BODY_2533
0 · Reply
ZacksResearch
ZacksResearch Jul. 18 at 11:50 AM
Can $OPRX break through the noise in digital health? It’s leaning on EHR-linked messaging and geo-targeting to differentiate — but scaling in a fiercely competitive space is the real test. Full breakdown here 👉 https://www.zacks.com/stock/news/2591316/can-oprxs-patient-engagement-tools-win-amid-fierce-competition?cid=sm-stocktwits-2-2591316-teaser-2480&ADID=SYND_STOCKTWITS_TWEET_2_2591316_TEASER_2480
0 · Reply
Doozio
Doozio Jul. 17 at 2:20 AM
$OPRA $OPRX obviously. 🐒🍌🧠⏰♾️
0 · Reply
Latest News on OPRX
OptimizeRx: Stock Could Rise As Profitability Is Achieved

Jul 18, 2025, 3:47 PM EDT - 12 days ago

OptimizeRx: Stock Could Rise As Profitability Is Achieved


OptimizeRx to Participate in Upcoming Investor Conferences

May 16, 2025, 7:30 AM EDT - 2 months ago

OptimizeRx to Participate in Upcoming Investor Conferences


OptimizeRx Corporation (OPRX) Q1 2025 Earnings Call Transcript

May 12, 2025, 9:56 PM EDT - 2 months ago

OptimizeRx Corporation (OPRX) Q1 2025 Earnings Call Transcript


OptimizeRx Corporation (OPRX) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 11:04 AM EDT - 5 months ago

OptimizeRx Corporation (OPRX) Q4 2024 Earnings Call Transcript


OptimizeRx Corporation (OPRX) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 10:58 PM EST - 9 months ago

OptimizeRx Corporation (OPRX) Q3 2024 Earnings Call Transcript


OptimizeRx Corporation (OPRX) Q1 2024 Earnings Call Transcript

May 14, 2024, 11:21 PM EDT - 1 year ago

OptimizeRx Corporation (OPRX) Q1 2024 Earnings Call Transcript


OptimizeRx Reports First Quarter 2024 Financial Results

May 14, 2024, 4:01 PM EDT - 1 year ago

OptimizeRx Reports First Quarter 2024 Financial Results


OptimizeRx Corporation (OPRX) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 11:20 AM EDT - 1 year ago

OptimizeRx Corporation (OPRX) Q4 2023 Earnings Call Transcript


OptimizeRx Reports Third Quarter 2023 Financial Results

Nov 6, 2023, 7:00 AM EST - 1 year ago

OptimizeRx Reports Third Quarter 2023 Financial Results


OptimizeRx Expands AI Powered Omnichannel Platform

Aug 24, 2023, 8:00 AM EDT - 2 years ago

OptimizeRx Expands AI Powered Omnichannel Platform


OptimizeRx Corporation (OPRX) Q2 2023 Earnings Call Transcript

Aug 14, 2023, 6:54 PM EDT - 2 years ago

OptimizeRx Corporation (OPRX) Q2 2023 Earnings Call Transcript


OptimizeRx Reports Second Quarter 2023 Financial Results

Aug 14, 2023, 4:01 PM EDT - 2 years ago

OptimizeRx Reports Second Quarter 2023 Financial Results


OptimizeRx Aims For Growth After Swoon

Jul 21, 2023, 1:47 PM EDT - 2 years ago

OptimizeRx Aims For Growth After Swoon


OptimizeRx's CEO Provides 2023 Midyear Strategic Update

May 24, 2023, 7:30 AM EDT - 2 years ago

OptimizeRx's CEO Provides 2023 Midyear Strategic Update


Eastern_Edge
Eastern_Edge Jul. 29 at 5:10 PM
$OPRX Bears completely silent after year end and Q1 earnings. Sad bears absolutely obliterated into the shadow realm LMAO
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 28 at 11:08 PM
$OPRX Excellent article that nails exactly where OPRX stands right now. So if you want to update your OPRX knowledge or get acquainted with OPRX, this is a must read. https://beyondspx.com/article/optimizerx-leveraging-integrated-tech-and-data-for-profitable-growth-nasdaq-oprx
0 · Reply
ZacksResearch
ZacksResearch Jul. 25 at 4:40 PM
$OPRX — Is this digital health player the real deal? 🚀 OptimizeRx delivered 11% year-over-year revenue growth and a shift to a subscription model in Q1 2025, with over 5% of projected annual revenues already converted to subscriptions. Despite risks like macro constraints and regulatory shifts, a Zacks Rank #1 suggests strong buy potential. See what makes the investment case strong for OptimizeRx 👉 https://www.zacks.com/stock/news/2616875/oprx-delivers-solid-q1-earnings-but-can-it-sustain-the-momentum?cid=sm-stocktwits-2-2616875-body-3835&ADID=SYND_STOCKTWITS_TWEET_2_2616875_BODY_3835
0 · Reply
ZacksResearch
ZacksResearch Jul. 25 at 12:29 PM
$OPRX delivers solid Q1 — but can it keep up the pace? 11% revenue growth and improved EBITDA show strength, but long-term upside depends on scaling subscriptions and margin mix improvements. Full momentum breakdown here 👉 https://www.zacks.com/stock/news/2616875/oprx-delivers-solid-q1-earnings-but-can-it-sustain-the-momentum?cid=sm-stocktwits-2-2616875-teaser-3818&ADID=SYND_STOCKTWITS_TWEET_2_2616875_TEASER_3818
0 · Reply
WOLFSTREET
WOLFSTREET Jul. 25 at 9:04 AM
$OPRX is on a CC LIST, play this horse until it runs out, and it has a ways to go, then move your winnings to $GDRX , the sleeping pills should have worn off by then, but otherwise you can just check back with CC for a 60 second update. I promise its quick, I just did both in less than 2 minutes.
0 · Reply
WOLFSTREET
WOLFSTREET Jul. 25 at 9:00 AM
Only reason $OPRX is beating $GDRX on the track is because OPRX has been chosen by the market to run, while market has GDRX on sleeping pills. Things will flip when pills wear off.
0 · Reply
tijsd
tijsd Jul. 23 at 2:27 PM
$PAYS if your bullish on pays, check $OPRX
0 · Reply
ZacksResearch
ZacksResearch Jul. 18 at 1:28 PM
$OPRX up 187.9% YTD — still room to run? 🚀 💡 11% year-over-year revenue growth and a 25% script lift highlight its strategic value. 🔍 With over 80% of 2025 revenues already contracted, the shift to subscription-based models offers margin stability. Discover why OPRX's transformation might be just getting started 👉 https://www.zacks.com/stock/news/2591316/can-oprxs-patient-engagement-tools-win-amid-fierce-competition?cid=sm-stocktwits-2-2591316-body-2533&ADID=SYND_STOCKTWITS_TWEET_2_2591316_BODY_2533
0 · Reply
ZacksResearch
ZacksResearch Jul. 18 at 11:50 AM
Can $OPRX break through the noise in digital health? It’s leaning on EHR-linked messaging and geo-targeting to differentiate — but scaling in a fiercely competitive space is the real test. Full breakdown here 👉 https://www.zacks.com/stock/news/2591316/can-oprxs-patient-engagement-tools-win-amid-fierce-competition?cid=sm-stocktwits-2-2591316-teaser-2480&ADID=SYND_STOCKTWITS_TWEET_2_2591316_TEASER_2480
0 · Reply
Doozio
Doozio Jul. 17 at 2:20 AM
$OPRA $OPRX obviously. 🐒🍌🧠⏰♾️
0 · Reply
ZacksResearch
ZacksResearch Jul. 16 at 1:39 PM
$OPRX or $GDRX: Which digital health play has more upside? 🤔 📈 OPRX surged 166.8% YTD with momentum in digital pharma engagement and subscription revenue contributing to its growth. 💰 GDRX up 2.1%, leveraging brand strength and expanding retail partnerships. Discover why OPRX might be the better buy with its Zacks Rank #1 👉 https://www.zacks.com/stock/news/2585294/oprx-vs-gdrx-which-health-tech-stock-has-stronger-revenue-momentum?cid=sm-stocktwits-2-2585294-body-2008&ADID=SYND_STOCKTWITS_TWEET_2_2585294_BODY_2008
0 · Reply
ZacksResearch
ZacksResearch Jul. 16 at 12:45 PM
$OPRX vs. $GDRX — which health tech name is really delivering? OPRX is riding high on rising subscription revenue and strong pharma demand, while GDRX is dragging from slower consumer growth. Full momentum breakdown here 👉 https://www.zacks.com/stock/news/2585294/oprx-vs-gdrx-which-health-tech-stock-has-stronger-revenue-momentum?cid=sm-stocktwits-2-2585294-teaser-1970&ADID=SYND_STOCKTWITS_TWEET_2_2585294_TEASER_1970
0 · Reply
ZacksResearch
ZacksResearch Jul. 11 at 4:55 PM
$OPRX surges 173.3% YTD — is this just the beginning? 🚀 🔥 First-quarter revenue up 11% YoY; Adjusted EBITDA hits $1.5M in Q1 📈 Full-year revenue guidance raised to $101-$106M 📊 Forward P/S of 2.22X vs. industry’s 8.86X — undervalued gem? Discover the full potential of OPRX’s strategic evolution here 👉 https://www.zacks.com/stock/news/2573186/optimizerx-bets-on-ai-and-workflow-integration-will-this-pay-off?cid=sm-stocktwits-2-2573186-body-1319&ADID=SYND_STOCKTWITS_TWEET_2_2573186_BODY_1319
0 · Reply
ZacksResearch
ZacksResearch Jul. 11 at 12:40 PM
$OPRX is going all-in on AI and subscriptions — smart pivot or risky gamble? They're leaning hard into platform integration, but margin pressure and retention risks could bite if execution slips. Full breakdown on the platform shift 👉 https://www.zacks.com/stock/news/2573186/optimizerx-bets-on-ai-and-workflow-integration-will-this-pay-off?cid=sm-stocktwits-0-2573186-teaser-1283&ADID=SYND_STOCKTWITS_TWEET_0_2573186_TEASER_1283
0 · Reply
ZacksResearch
ZacksResearch Jul. 3 at 1:43 PM
$OPRX surges 69.3% in 3 months — what's driving this explosive growth? 🚀 📈 Revenue up 11% YoY with strong cash flow 🔄 Transition to subscription model gaining traction 📊 Raised FY guidance with more than 25% YoY increase in committed contracted revenue, now exceeding $70 million Discover the full growth story here 👉 https://www.zacks.com/commentary/2561912/oprx-shares-rise-693-in-3-months-time-to-bet-on-the-stock?cid=sm-stocktwits-2-2561912-body-706&ADID=SYND_STOCKTWITS_TWEET_2_2561912_BODY_706
0 · Reply
JarvisFlow
JarvisFlow Jun. 9 at 5:45 PM
Stifel updates rating for OptimizeRx ( $OPRX ) to Buy, target set at 12.5 → 16.
0 · Reply
Doozio
Doozio Jun. 6 at 11:04 PM
$OPRA and all da 🐑 been SPOT so scrabble bag it $OPRX during 🐒🍌🧠⏰♾️ as “allegedly” becomes obviously!
0 · Reply
Gergely_Blasko
Gergely_Blasko Jun. 6 at 1:58 PM
$OPRX it should pullback to skyrocket. I am bearish short therm (1-2 month).
0 · Reply
kgnfdeagle
kgnfdeagle Jun. 5 at 3:28 PM
$OPRX Added to Homerun portfolio by Brian Bolan at Zacks -- bought 200x at $15.00.
2 · Reply
Maissessap
Maissessap May. 14 at 9:10 AM
$OPRX https://www.tipranks.com/news/the-fly/optimizerx-price-target-raised-to-22-from-16-at-roth-capital
0 · Reply
om8144
om8144 May. 13 at 10:27 PM
$OPRX https://www.tipranks.com/news/the-fly/optimizerx-price-target-raised-to-18-from-13-at-b-riley
0 · Reply
JarvisFlow
JarvisFlow May. 13 at 4:27 PM
Stifel has updated their rating for OptimizeRx ( $OPRX ) to Buy with a price target of 12.5.
0 · Reply